ClinicalTrials.gov
ClinicalTrials.gov Menu

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00005970
Recruitment Status : Active, not recruiting
First Posted : January 27, 2003
Last Update Posted : August 22, 2017
Sponsor:
Collaborators:
Cancer and Leukemia Group B
Eastern Cooperative Oncology Group
Canadian Cancer Trials Group
Southwest Oncology Group
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : November 15, 2009
  Study Completion Date : No date given
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):